Skip to main content

Table 4 LDR versus HDR for overall mortality, local recurrence and late complications

From: Brachytherapy for cervix cancer: low-dose rate or high-dose rate brachytherapy – a meta-analysis of clinical trials

Overall mortality

Stage

Number of studies

Total patients

Patients/events

HDR

Patients/events

LDR

OR

CI95%

P value

I

2

134

19/67

13/67

0.68

0.36–1.29

0.23

II

4

500

75/257

62/243

0.84

0.56–1.24

0.38

III

5

1079

238/572

228/507

1.22

0.95–1.56

0.11

Local recurrence

Stage

Number of studies

Total patients

Patients/events

HDR

Patients/events

LDR

OR

CI95%

P value

I

2

134

7/67

3/67

2.31

0.61–8.71

0.22

II

4

500

45/257

34/243

1.17

0.74–1.85

0.51

III

5

1079

143/572

138/507

0.94

0.70–1.27

0.70

Grade 3 or 4 rectal complication

 

Number of studies

Total patients

Patients/events

HDR

Patients/events

LDR

OR

CI95%

P value

 

5

2065

27/1068

27/997

0.9

0.52–1.56

0.7

Grade 3 or 4 bladder complication

 

Number of studies

Total patients

Patients/events

HDR

Patients/events

LDR

OR

CI95%

P value

 

5

2065

17/1068

16/997

0.98

0.49–1.96

0.95

Grade 3 or 4 small intestine complication

 

Number of studies

Total patients

Patients/events

HDR

Patients/events

LDR

OR

CI95%

P value

 

3

783

13/432

3/351

3.15

0.9–10.37

0.06